Value proposition

Disruptive Technology for Molecular Diagnostics based on Ultrabright Fluorescent Nanoparticles

The current limitations of molecular diagnostics, such as PCR, do not allow for rapid screening and personalized follow-up of cancers and viral diseases. Healthcare professionals and institutions are therefore looking for simple, rapid and cost-effective tests for screening and monitoring patients.
BrightSens Diagnostics will provide the solution to these needs by offering highly sensitive Point of Care tests. Our patented technology, with unique properties, is the result of 10 years of research supported by 2 ERC contracts with over 2M Euros.
Our ultra-bright and ultra-sensitive fluorescent NanoAntennas amplify a detection signal. They allow direct measurement of very low concentrations of RNA - disease biomarkers - without enzymes, by simple fluorescence measurement. Our Point of Care tests will revolutionize molecular diagnostics.